XtalPi Holdings Ltd., a global leader in integrating artificial intelligence and robotics for the advancement of medical and materials science, has announced an expansion of its strategic collaboration with Pfizer. This partnership aims to develop a next-generation molecular modeling platform for drug discovery. By combining advanced physics-based methods with cutting-edge AI technology, the collaboration seeks to improve accuracy, speed, and scalability in small molecule drug discovery and development. XtalPi will leverage its XFEP platform to enhance Pfizer's proprietary chemical space, empowering diverse drug design and development scenarios. The partnership is poised to deliver transformative predictive tools, accelerating the creation of groundbreaking therapies for patients worldwide.